Interestingly, the treatment with brodalumab, a competitive inhibitor of the IL-17 receptor A subunit, reduced MIAT expression in psoriatic skin lesions (Figure S10), suggesting MIAT is involved in other Th17 related autoimmune disorders. Here, IL17RA is linked to autoimmune disease.